Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $23.3333.

A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. BTIG Research began coverage on shares of Zevra Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $23.00 price target for the company. Finally, Guggenheim upped their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th.

Zevra Therapeutics Price Performance

ZVRA opened at $11.17 on Friday. The company has a fifty day moving average price of $10.29 and a 200-day moving average price of $9.36. The firm has a market capitalization of $660.37 million, a P/E ratio of 5.61 and a beta of 0.91. Zevra Therapeutics has a one year low of $7.16 and a one year high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. On average, analysts expect that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its position in Zevra Therapeutics by 12.3% during the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock valued at $114,000 after buying an additional 1,390 shares during the period. The Manufacturers Life Insurance Company boosted its position in Zevra Therapeutics by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after buying an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after acquiring an additional 1,812 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Zevra Therapeutics by 4.4% during the fourth quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock valued at $412,000 after acquiring an additional 1,936 shares during the last quarter. Finally, MetLife Investment Management LLC raised its stake in shares of Zevra Therapeutics by 10.5% during the fourth quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock valued at $250,000 after acquiring an additional 2,653 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.